1019-P: Variability of 501 Inhaled Insulin Absorption and Action

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1019-P
Author(s):  
ERIC ZIJLSTRA ◽  
GRIT ANDERSEN ◽  
LEONA PLUM-MOERSCHEL ◽  
MELISSA RHODES ◽  
RYAN PATTON ◽  
...  
Keyword(s):  
Insulin Absorption ◽  
Inhaled Insulin

Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1017-P ◽  
Author(s):  
JANET K. SNELL-BERGEON ◽  
HALIS K. AKTURK ◽  
AMANDA REWERS ◽  
BRUCE W. BODE ◽  
LESLIE J. KLAFF ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Continuous Glucose Monitor ◽  
Inhaled Insulin ◽  
Time In Range

Safety of Technosphere Inhaled Insulin

2017 ◽  
Vol 12 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Nasser Mikhail
Keyword(s):  
Inhaled Insulin

scholarly journals Inhaled Insulin: Intrapulmonary or Intranasal?

2012 ◽  
Author(s):  
Danish Ahmed ◽  
Sweta Kumari ◽  
Shruti Mishra ◽  
Shivangi Jaiswal
Keyword(s):  
Inhaled Insulin

scholarly journals Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery

2019 ◽  
Vol 87 (3) ◽  
pp. 20 ◽  
Author(s):  
Miléna Lengyel ◽  
Nikolett Kállai-Szabó ◽  
Vince Antal ◽  
András József Laki ◽  
István Antal
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Freeze Drying ◽  
Delivery Systems ◽  
The Novel ◽  
Practical Applications ◽  
Inhaled Insulin ◽  
Formulation Factors ◽  
Novel Drug ◽  
Significant Production

Microparticles, microspheres, and microcapsules are widely used constituents of multiparticulate drug delivery systems, offering both therapeutic and technological advantages. Microparticles are generally in the 1–1000 µm size range, serve as multiunit drug delivery systems with well-defined physiological and pharmacokinetic benefits in order to improve the effectiveness, tolerability, and patient compliance. This paper reviews their evolution, significance, and formulation factors (excipients and procedures), as well as their most important practical applications (inhaled insulin, liposomal preparations). The article presents the most important structures of microparticles (microspheres, microcapsules, coated pellets, etc.), interpreted with microscopic images too. The most significant production processes (spray drying, extrusion, coacervation, freeze-drying, microfluidics), the drug release mechanisms, and the commonly used excipients, the characterization, and the novel drug delivery systems (microbubbles, microsponges), as well as the preparations used in therapy are discussed in detail.

scholarly journals The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day

2018 ◽  
Vol 12 (2) ◽  
pp. 273-281 ◽  
Author(s):  
Roberto Visentin ◽  
Enrique Campos-Náñez ◽  
Michele Schiavon ◽  
Dayu Lv ◽  
Martina Vettoretti ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
In Silico ◽  
Artificial Pancreas ◽  
Real Life ◽  
Glucose Monitoring ◽  
Glucose Variability ◽  
Self Monitoring ◽  
Inhaled Insulin ◽  
Single Meal

Background: A new version of the UVA/Padova Type 1 Diabetes (T1D) Simulator is presented which provides a more realistic testing scenario. The upgrades to the previous simulator, which was accepted by the Food and Drug Administration in 2013, are described. Method: Intraday variability of insulin sensitivity (SI) has been modeled, based on clinical T1D data, accounting for both intra- and intersubject variability of daily SI. Thus, time-varying distributions of both subject’s basal insulin infusion and insulin-to-carbohydrate ratio were calculated and made available to the user. A model of “dawn” phenomenon based on clinical T1D data has been also included. Moreover, the model of subcutaneous insulin delivery has been updated with a recently developed model of commercially available fast-acting insulin analogs. Models of both intradermal and inhaled insulin pharmacokinetics have been included. Finally, new models of error affecting continuous glucose monitoring and self-monitoring of blood glucose devices have been added. Results: One hundred in silico adults, adolescent, and children have been generated according to the above modifications. The new simulator reproduces the intraday glucose variability observed in clinical data, also describing the nocturnal glucose increase, and the simulated insulin profiles reflect real life data. Conclusions: The new modifications introduced in the T1D simulator allow to extend its domain of validity from “single-meal” to “single-day” scenarios, thus enabling a more realistic framework for in silico testing of advanced diabetes technologies including glucose sensors, new insulin molecules and artificial pancreas.

Sign in / Sign up

Export Citation Format

Share Document